SZN-413, a FZD4 Agonist, as a Potential Novel Therapeutic for the Treatment of Diabetic Retinopathy

PURPOSE: There remains a high unmet need for therapies with new mechanisms of action to achieve reperfusion of ischemic retina in diabetic retinopathy. We examined whether a novel frizzled class receptor 4 (FZD4) agonist could promote regeneration of functional blood vessels in animal models of reti...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Huy, Chen, Hui, Vuppalapaty, Meghah, Whisler, Elizabeth, Logas, Kelsey Ronarda, Sampathkumar, Parthasarathy, Fletcher, Russell Byron, Sura, Asmiti, Suen, Nicholas, Gupta, Suhani, Lopez, Tom, Ye, Jay, Tu, Shengjiang, Bolaki, Menaka, Yeh, Wen-Chen, Li, Yang, Lee, Sung-Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Association for Research in Vision and Ophthalmology 2022
Materias:
Retina
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520515/
https://www.ncbi.nlm.nih.gov/pubmed/36149648
http://dx.doi.org/10.1167/tvst.11.9.19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520515/
https://www.ncbi.nlm.nih.gov/pubmed/36149648
http://dx.doi.org/10.1167/tvst.11.9.19

Ejemplares similares